Andere Sprachen Adlai Nortye Ltd.

Aktien

A3EEED

US00704R1095

ANL

Verzögert Nasdaq Andere Börsenplätze 16:23:11 28.06.2024			% 5 Tage	% 1. Jan.
3,26 ^USD	-12,12 %		-10,68 %	-63,74 %

24.05.	Adlai Nortye Ltd. kündigt an, ermutigende Daten zur Kombination von AN0025 und definitiver Chemoradiotherapie (dCRT) auf dem ASCO 2024 zu präsentieren	CI
22.05.	Adlai Nortye gibt die Verabreichung des ersten Patienten in der randomisierten klinischen Phase-Ii-Studie mit Palupiprant (An0025) zur Behandlung von lokal fortgeschrittenem Rektalkrebs mit Strahlentherapie bekannt	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Adlai Nortye : U.S. Securities and Exchange Commission Form 6 K	27.06.
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024	24.05.
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024	24.05.
Adlai Nortye Ltd. Announces to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy At ASCO 2024	24.05.
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy	22.05.
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy	22.05.
Adlai Nortye Announces First Patient Dosed in Randomized Phase Ii Clinical Trial of Palupiprant for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy	22.05.
ADRs Advance, Eco Wave Power Global AB Climbs 213.4%	08.04.
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development	01.04.
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development	29.03.
Adlai Nortye Announces Appointment of Archie Tse as the Head of Research & Development	29.03.
Certain Class B Ordinary Shares of Adlai Nortye Ltd. are subject to a Lock-Up Agreement Ending on 28-MAR-2024.	28.03.
Certain Class A Ordinary Shares of Adlai Nortye Ltd. are subject to a Lock-Up Agreement Ending on 28-MAR-2024.	28.03.
Adlai Nortye : Term of use	06.12.
Adlai Nortye Says it has Completed Patient Enrollment in Phase 3 Trial of Buparlisib	17.11.
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC	17.11.
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC	17.11.
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC	17.11.
Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award	23.10.23
Adlai Nortye : in collaboration with Nucleai, to Present "Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN" at ESMO 2023	16.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Adlai Nortye Ltd.

Aktien

A3EEED

US00704R1095

ANL

Andere Sprachen

Filter